NCT06419946RecruitingPhase 3
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Phase III Trial of Temozolomide/Lomustine (TMZ/LOM) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT Promoter Methylated Glioblastoma (IDHwt) Patients +/- Tumor Treating Fields (Optune)
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
Background: Glioblastoma (GBM) is notoriously difficult to treat, with current therapies often extending life by only a few months. The standard treatment involves surgery followed by radiation and chemotherapy with Temozolomide (TMZ). The efficacy of TMZ, however, is significantly enhanced when the tumor's o6-methylguanine-DNA-methyltransferase (MGMT) gene is methylated. Recent studies, such as the NOA-09 trial, have suggested that adding Lomustine (LOM) to TMZ could improve outcomes for patients with this specific tumor profile. Hypothesis: The investigators hypothesize that the addition of LOM to the TMZ regimen will lead to significantly improved survival rates among patients with newly diagnosed glioblastoma who have a methylated MGMT promoter compared to those receiving only TMZ. Treatment Plans: The study will randomly assign participants to two groups: * Control Group: Standard treatment with TMZ during and after radiation therapy. * Experimental Group: TMZ combined with LOM, starting on the first day of radiation therapy. Outcome Measures: The primary outcome measure will be survival. Other outcomes will include progression-free survival (time from randomization until tumor progression or death), safety profiles (adverse effects of the treatments), and quality of life measures as well as neurocognitive outcomes.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 29 Apr 2024
- Start date
- 1 Feb 2025
- Primary completion date
- 15 Dec 2031
- Lead sponsor
- Vastra Gotaland Region
- Diseases
- Glioblastoma
- NCT number
- NCT06419946
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 200
- From 1 Feb 2025 to the primary completion date, 15 Dec 2031
- 20 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous chemotherapy or radiotherapy involving the head
Other illness
- Previous malignancy within 3 y or malignancy treated non-curatively
Other
- Off-protocol tumor-specific treatment
- Serious comorbidity
Who the study is looking for
- Newly diagnosed glioblastoma/gliosarcoma, IDH wild type
- Methylated MGMT promoter
- World Health Organization performance status 0-2
- Age 18-70
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (20)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Graz Coordinator of this site? Confirm its status | Graz | Austria | Not yet recruiting |
| Medizinische Universität Innsbruck Coordinator of this site? Confirm its status | Innsbruck | Austria | Not yet recruiting |
| Kepler University Hospital Coordinator of this site? Confirm its status | Linz | Austria | Recruiting |
| University Hospital St. Pölten Coordinator of this site? Confirm its status | Sankt Pölten | Austria | Enrolling by invitation |
| Aarhus University Hospital Coordinator of this site? Confirm its status | Aarhus | Denmark | Recruiting |
| Haukeland University Hospital Coordinator of this site? Confirm its status | Bergen | Norway | Recruiting |
| Sorlandet Sykehus Coordinator of this site? Confirm its status | Kristiansand | Norway | Recruiting |
| Oslo University Hospital Coordinator of this site? Confirm its status | Oslo | Norway | Recruiting |
| Stavanger University Hospital Coordinator of this site? Confirm its status | Stavanger | Norway | Not yet recruiting |
| St Olavs Hospital Coordinator of this site? Confirm its status | Trondheim | Norway | Not yet recruiting |
| Gävle Hospital Coordinator of this site? Confirm its status | Gävle | Sweden | Recruiting |
| Sahlgrenska University Hospital Coordinator of this site? Confirm its status | Gothenburg | Sweden | Recruiting |
| Ryhov County Hospital Coordinator of this site? Confirm its status | Jönköping | Sweden | Recruiting |
| Kalmar Country Hospital Coordinator of this site? Confirm its status | Kalmar | Sweden | Recruiting |
| Skåne University Hospital Coordinator of this site? Confirm its status | Lund | Sweden | Not yet recruiting |
| Örebro University Hospital Coordinator of this site? Confirm its status | Örebro | Sweden | Recruiting |
| Karolinska Institutet Coordinator of this site? Confirm its status | Stockholm | Sweden | Enrolling by invitation |
| Sundsvall Hospital Coordinator of this site? Confirm its status | Sundsvall | Sweden | Enrolling by invitation |
| Norrlands Universitetssjukhus, Umea, Sweden Coordinator of this site? Confirm its status | Umeå | Sweden | Recruiting |
| Uppsala University Hospital Coordinator of this site? Confirm its status | Uppsala | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.